Adrafinil
Adrafinil is a compound that is metabolized to modafinil and armodafinil in the body. Although modafinil is a controlled substance in most countries, adrafinil is largely unscheduled. In the United States, it is treated as a "supplement" despite having active metabolites that are recognized and regulated as drugs.
Legality and Availability[edit]
Modafinil[edit]
The United States is one of the only countries which considers modafinil a controlled substance. It is classified as Schedule IV under the CSA.
Canada and the United Kingdom classify modafinil as prescription-only, but uncontrolled. Australia classifies it as Schedule 4 (prescription only, uncontrolled).
Armodafinil[edit]
Legal Status | ||
---|---|---|
US | Rx Only (Schedule IV) | |
Drug Information | ||
FDA Status | Drug | |
Class | Stimulant | |
Addiction Risk | Low | |
Brand Names | ![]() ![]() ![]() ![]() |
The United States classifies armodafinil as a Schedule IV controlled substance.
Other countries typically regulate it as prescription-only but uncontrolled, similar to modafinil.
Adrafinil[edit]
Legal Status | ||
---|---|---|
US | Legal, unscheduled | |
Canada | ||
AU | Rx Only (Schedule 4) | |
Drug Information | ||
FDA Status | Unregulated | |
Class | Stimulant | |
Addiction Risk | Low |
A prodrug to modafinil and armodafinil, adrafinil is largely unregulated. It is absent from the list of controlled substances in the United States.
Adrafinil was marketed in France under the brand name Olmifon until it was discontinued in 2011, as it was considered analogous to the already marketed modafinil.